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Abstract
Background
Neurological complications are common following cardiothoracic surgery using cardiopulmonary bypass; these can range 
from episodes of temporary delirium to severely debilitating strokes. Despite strong evidence showing the involvement of 
lipid microemboli, there is currently no established method for the effective removal of these particles. We conceived the 
study described here to evaluate the clinical use of a new integral lipid filter in reducing lipid microemboli and to determine 
the impact on markers of cerebral and renal injury and pulmonary dysfunction during the cardiopulmonary bypass period.
Methods/Design
Fifty patients undergoing routine coronary artery bypass grafting using cardiopulmonary bypass will be randomised to either 
the intervention group, receiving the integral lipid filter during surgery, or a control group which does not. All clinicians and 
patients will be blinded as to their method of treatment. Measurements of lipid emboli will be taken throughout the surgical 
period with biochemical markers measured throughout the surgical and postoperative period. 
Discussion
Limited success has been found in removing lipid microemboli using currently available methods. An integral lipid filter may 
well fulfill this role and help reduce the associated morbidity. This paper reports the design and methods for a randomized 
controlled trial comparing the outcomes of the RemoweLL lipid and leucocyte removing filter with standard equipment for 
patients undergoing coronary artery bypass grafting using cardiopulmonary bypass.
Trial registration
International Standard Randomised Controlled Trial Number Register: ISRCTN56462370
EudraCT Number: 2009-011503-23
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BACKGROUND
The Role of Cardiopulmonary Bypass
Cardiopulmonary bypass (CPB) using 
an Extracorporeal Circuit (ECC) fa-
cilitates surgical intervention of the 
heart. CPB carries out the functions 
of the heart and the lungs during sur-
gery allowing the surgeon to operate 
on a flaccid, bloodless environment. 
It requires the removal and subse-
quent return of the patient’s entire 
circulating blood volume An ECC cir-
cuit consists of 4 major components; 
a venous reservoir, an arterial pump, 
an oxygenator and an arterial line 
filter (Figure 1). The deoxygenated 
blood enters the venous reservoir 
from a cannula in the right atrial ap-
pendage. The venous reservoir (1a) 
serves two purposes; acting as a ca-
pacitance chamber and a filter. As 
a capacitance chamber, the venous 
reservoir can cope with acute volume 
shifts that occur as a result of surgical 
manipulation of the heart. The reser-
voir contains a central column of po-
rous plastic foam and a polypropyl-
ene woven screen providing filtration 
to at least 40µm. This filter removes 
any particulate matter or gaseous 
emboli that should enter the circuit 
via the venous cannula. From the 
venous reservoir, blood passes into 
the arterial pump which functions as 
the ventricles of the heart, pumping 
blood around the body. There are 
two types of arterial pump; centrif-
ugal (2a) and roller (2b). When the 
blood leaves the arterial pump it en-
ters the oxygenator (3); this is made 
of porous polypropylene membrane 
arranged into hollow fibres. Integral 
to the oxygenator is a plastic coat-
ed aluminium heat exchanger that 
enables control of the blood (and 
therefore the patient’s) temperature 
during the operation. The oxygena-
tor works on a similar concept to the 
lungs; it has a large surface area but 
with tiny holes in the hollow fibres 
creating a virtual blood-gas interface 
allowing the addition and removal of 
oxygen and carbon dioxide respec-
tively. The final component is the 
arterial line filter (4), which removes 
any further microparticles before re-
turn to patient and is a gaseous bub-
ble trap.
Whilst the CPB circuit is made of 
non-toxic, non-immunogenic mate-
rials such as polycarbonate and pol-
yvinyl chloride, blood contact with 
the artificial surfaces of the circuit 
causes activation of the clotting cas-
cade. To enable CPB to take place full 
anticoagulation is required. This is at-
tained using Heparin, which has the 
added advantage of being able to be 
reversed using protamine once the 
operation is completed.
There are various components that 
can be added to the CPB circuit de-
pending on the diagnosis and treat-
ment of the patient. A separate cardi-
otomy suction reservoir can be added 
to manage low pressure suction of 
blood from the open chest cavity. 
This blood contains the major source 
of microemboli and activated inflam-
matory markers (discussed in more 
detail later).
Despite the extremely low mortality 
Figure 1. Componenets of the CPB circuit. 
1, Venous Reservoir. 2a, Centrifugal Arterial Pump. 2b Roller Arterial Pump. 3, 
Oxygenator. 4, Arterial Line Filter. See text for details.
and morbidity rates of CABG surgery 
involving Cardiopulmonary Bypass 
(CPB), there are a number of patho-
logical injuries associated with the 
CPB circuit. Lipid Microemboli (LME) 
(produced when performing a ster-
notomy) mix with blood in the Per-
icardial Suction Blood (PSB) during 
surgery. This blood is passed into the 
CPB circuit and reintroduced into 
the systemic circulation, promoting 
an increased inflammatory response 
and impairing blood flow in capillar-
ies. At the same time, the action of 
blood coming into contact with the 
non-physiological surfaces of the CPB 
circuit causes a significant up-regu-
lation of the patient’s inflammatory 
system leading, in extreme cases, to 
a Systemic Inflammatory Response 
Syndrome (SIRS). One of the main 
components of this unregulated in-
flammatory response is activated leu-
cocytes, which attack sensitive organs 
such as the lungs.  
The RemoweLL (Eurosets, Mirandola, 
Italy) oxygenator contains a lipid and 
leucocyte filter. By filtering lipids and 
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removing activated leucocytes the 
severity of injury in sensitive organs 
such as the brain, kidneys and lungs 
should be reduced.
This paper reports the design and 
methods of a study  comparing  the 
ability of the RemoweLL to filter li-
pids and activated leucocytes out of 
the PSB with standard equipment 
and will assess the possible effects 
this has on cerebral and renal injury 
markers and pulmonary function dur-
ing and following CPB.
Incidence of Mortality and 
Morbidity
Whilst there has been a 21% de-
crease in mortality figures for pa-
tients undergoing CABG operations 
since 2001(Bridgewater 2009), it is 
estimated that 2-5% of patients un-
dergoing CABG suffer from stroke, 
with a further 20% experiencing de-
lirium-like symptoms. It has also been 
suggested that a further 50% of CABG 
patients exhibit Diffuse Brain Dam-
age (DBD), although higher and lower 
frequencies are reported by different 
groups (Engström 2004). The reason 
behind these varying types of mor-
bidity characteristics is not entirely 
known (Ali, Harmer et al. 2000). Fur-
thermore, it is not only the brain that 
suffers injury following CABG surgery; 
a recent review by Mehta has shown 
that up to 10% of patients experience 
Acute Renal Failure (ARF) which, in 
the most extreme examples, leads to 
dialysis treatment, renal transplant 
and even death (Mehta 2005) whilst 
the inflammatory reaction caused by 
CPB leads to 20% of patients requir-
ing ventilation times of more than 
48 hours due to pulmonary dysfunc-
tion. In the most serious cases an 
Acute Respiratory Distress Syndrome 
(ARDS) develops which has a 50% 
mortality rate (Schlensak and Beyers-
dorf 2005). Therefore, although over-
all mortality rates are decreasing, the 
morbidity associated with CPB re-
mains high.
The Pathological Effects 
of CPB
Inflammatory Response
The CPB circuit is made of large 
non-physiological surfaces which, 
when in contact with blood, invoke 
a complex inflammatory response. 
It is widely accepted that a systemic 
inflammatory response, is present in 
all patients following CPB (Sablotzki, 
Muhling et al. 2001) although the 
incidence and severity is variable, 
ranging from mildly detectable to 
the severe Multi Organ Dysfunction 
Syndrome (MODS) (Asimakopoulos 
1999).
The inflammatory response to CPB is 
initiated by numerous injuries to both 
the cellular and humoral elements of 
blood. The repeated passage of blood 
through the CPB circuit leads to con-
tact activation of coagulation factors 
XII, XI, prekallikrein and high molecu-
lar-weight kininogen. This leads to an 
activation cascade triggering the clas-
sical complement cascade (Wan, Le-
Clerc et al. 1997) disrupting haemo-
stasis which generates a whole-body 
inflammatory response.
Of particular interest is the activation 
of leucocytes and neutrophils fol-
lowing CPB, mediated by a number 
factors such as C3a, C5a and platelet 
activating factor (PAF) and associated 
with an increase in surface adhesion 
molecules CD11b/CD18 (Dreyer, Mi-
chael et al. 1995; Dreyer, Michael et 
al. 1995). The non-specific activity in-
duced in leucocytes by CPB leads to 
assaults on native endothelial cells 
resulting in cell destruction and SIRS 
(Matheis, Scholz et al. 2001). In par-
ticular, activated neutrophils are as-
sociated with postoperative pulmo-
nary dysfunction (Clark 2006), with 
high levels of neutrophil elastase, a 
measure of neutrophil activation, at 
the end of CPB. Although during CPB 
there is a fall in neutrophil count due 
to haemodilution and surface adhe-
sion, CPB-induced cytokines facilitate 
the release of neutrophils from the 
bone marrow and from vascular walls 
resulting in a net increase following 
CPB. Animal studies also suggest that 
activated neutrophils may contribute 
to myocardial ischaemia – reperfu-
sion injury (Youker, Hawkins et al. 
1994). Rinder and colleagues (Rinder, 
Bonan et al. 1992) determined that 
a leucocyte-platelet adhesion was 
formed in response to CPB resulting 
in increased activation of phagocytic 
cells. The use of leucocyte depleting 
filters has been the subject of much 
debate with a recent systematic re-
view (Warren, Alexiou et al. 2007) 
concluding that whilst there were 
many randomised controlled trials 
investigating leucocyte filtration, 
most were small and had limitations, 
i.e., were not able to detect clinically 
relevant endpoints, although some 
benefit was seen in a subsection of 
patients with certain co-morbidi-
ties. A beneficial effect of leucocyte 
depletion has been seen in patients 
with preoperative renal impairment 
(Tang, Alexiou et al. 2002). Mastran-
gelo et al., (Mastrangelo, Jeitner et al. 
1998) have shown that oleic acid (in 
the form of fat emboli), released fol-
lowing traumatic bone injury, induc-
es increased expression of CD11b on 
neutrophil surfaces. It has yet to be 
determined whether this activation 
of neutrophils may also cause cere-
bral and renal impairment, and more 
importantly, whether the filtration of 
lipids would cause less activation and 
therefore less ischaemic injury. 
Lipid Embolic Events
Since the advent of centrifugal pumps 
and membrane oxygenators, major 
neurological complications resulting 
from emboli occurring from spalla-
tion of silicone tubing (the shedding 
of silicone microparticles due to com-
pression and relaxation associated 
with roller pumps) within the CPB cir-
cuit and air have significantly reduced 
(Parolari, Alamanni et al. 2000). Re-
cently there has been interest in bi-
ological emboli such as aggregates 
of cells and/or lipid materials. Eng-
ström (Engström 2003) and Brooker 
et al., (Brooker, Brown et al. 1998) 
have reported diffuse brain damage 
following the recycling of PSB due to 
the microembolisation of liquid fat. It 
is reported that two thirds of the fat 
emboli developed within a CPB circuit 
enter through the cardiotomy suction 
(Jönsson, Eyjolfsson et al. 2009). The 
fat collects with PSB that when re-in-
troduced into the circulating volume 
is expelled via the aortic cannula into 
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the cerebral vessels leading to small 
capillary arterial dilations (SCADs). Fat 
emboli typically consist of denatured 
plasma lipoproteins and lipids whilst 
the fat recovered in plasma consists 
of chylomicron aggregates or triglyc-
eride and cholesterol-containing fat 
particles (de Vries, Gu et al. 2002). It 
is not only the cerebral vessels that 
are affected by LME; Brondén et al., 
(Brondén, Dencker et al. 2006) have 
shown LME uptake in all organs, es-
pecially the kidneys. Appelblad (Ap-
pelblad and Engström 2002) has also 
shown that liquid fat contained within 
the PSB highly impairs capillary flow 
function. The treatment of choice for 
fat containing PSB is of current dis-
cussion. The rationale for fat filtration 
proposed by de Vries et al., (de Vries, 
Gu et al. 2002) is sound in theory but 
practically difficult. Kincaid et al., at-
tempted to determine whether var-
ious leucocyte filtration methods in 
conjunction with cell salvage would 
prevent LME with little success (Kin-
caid, Jones et al. 2000). 
The treatment of PSB has been in-
tensively discussed and debated with 
some authors advocating the com-
plete disposal of PSB to reduce the 
associated pathologies (Appelblad 
and Engström 2002), whilst others 
propose the Cell Salvage (CS) of PSB 
to remove harmful inflammatory fac-
tors, LME and toxic plasma Free Hae-
moglobin (FHb) (Jewell, Akowuah et 
al. 2003; Svenmarker and Engström 
2003; Skrabal, Khosravi et al. 2006). 
Cell salvage involves the collection of 
shed blood from the operating field 
which is then centrifuged and washed 
with saline before returning to the 
patient; centrifugation removes plas-
ma, platelets and coagulation factors 
with the result that only RBCs are 
re-infused after processing. It should 
be noted however that the majority 
of these studies had small population 
sizes and therefore lacked the power 
to see clinically relevant outcomes 
such as ventilation times, postoper-
ative bleeding and long term neuro-
cognitive outcome. More recently the 
Cardiotomy Trial (Rubens, Boodhwani 
et al. 2007) carried out in Canada, a 
double-blinded Randomised Con-
trolled Trial (RCT) of 266 patients, 
comparing CS and rein   fusion of PSB 
and its influence on transfusion and 
Postoperative Cognitive Dysfunction 
(POCD) concluded:
    1. Whilst no significant differences 
were seen between groups in terms 
of neurocognitive outcome, POCD 
was higher in the treatment group 
than the control group (45.3% vs. 
39%).
      2. The CS group had a higher (al-
though not significant) Red Blood 
Cell (RBC) transfusion rate (42% vs. 
36%) as well as higher overall non-
RBC transfusion rate (2.06±7.70 vs. 
1.12±4.74 units/patient).
        3. Postoperative chest drainage 
was significantly higher in the CS 
group (p=0.04).
      4. CS resulted in a significant re-
duction in postoperative platelet 
count (p=0.05) and caused significant 
coagulation abnormalities with the 
Partial Thromboplastin Time (PTT) 
and International Normalised Ratio 
(INR) significantly increased (p<0.01).
However, the authors also found in a 
subset of patients (n=154) that PSB 
processing with CS improved the 
cardiovascular and haemodynamic 
performance but did not significantly 
improve the mechanical pulmonary 
function or gas exchange (Boodhwani, 
Nathan et al. 2008). Therefore the 
question over how best to remove 
the pathological effects of PSB re-
mains unsolved, especially as these 
studies clearly demonstrate current 
methods cannot remove LME, and 
are furthermore associated with ad-
verse outcomes (increased bleeding 
and POCD). To this end, the study 
aims to determine if the RemoweLL 
lipid and leucocyte removing filter 
can provide an alternative, method of 
PSB processing which includes LME 
removal. 
As yet no research has been pub-
lished investigating a dedicated lipid 
filtration device on cerebral and renal 
injury markers and pulmonary func-
tion, despite strong supporting evi-
dence. 
The RemoweLL oxygenator is the first 
and only CPB circuit that incorporates 
a lipid and leucocyte depleting filter 
within the cardiotomy reservoir. The 
main aims of this research will be to;
       1. Quantify the reduction of lipid 
microemboli, in the pericardial suc-
tion blood, and activated leucocytes, 
returning into circulation.
         2. Determine the effect of lipid 
and leucocyte filtration on renal inju-
ry markers.
         3. Determine the effect of lipid 
and leucocyte filtration on cerebral 
injury markers.
         4. Determine the effect of lipid 




The study will be a blinded, ran-
domised control trial of the Re-
moweLL oxygenator, compared to a 
current standard oxygenator, the Ad-
miral. The two circuits  are identical 
and therefore indistinguishable to the 
Surgeon and Anaesthetist, so allow-
ing the study to be double-blinded. 
The laboratory staff undertaking the 
test procedures will also be blind-
ed to the treatment allocation. The 
subjects, patients undergoing CABG 
surgery, will be involved in the study 
that will last 5 days from the day of 
surgery. The study is expected to take 
two (2) years.
Participants
The study will include participants 
with ischaemic heart disease requir-
ing coronary artery bypass grafting 
between the ages 18 and 90. Whilst 
the number of blood samples re-
quired is high (11 in total), due to the 
haemodilutive nature of CPB, the ef-
fects on the patients’ blood volume is 
negligible. A more details list of eligi-
bility criteria is given in table 1.
Study Settings
The Perfusion department of Uni-
versity Hospitals Southampton NHS 
Foundation Trust will be responsible 
for recruiting and treating all patients 
in this study. The Research and Devel-
opment department will be respon-
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sible for medical device safely, and 
University of Southampton will be re-
sponsible for the data management 
and statistical analyses.
Objectives
The primary objective is to determine 
the efficacy of the RemoweLL lipid 
and leucocyte depleting filter on re-
ducing the numbers of activated leu-
cocytes and removing the LME load 
of patients undergoing CABG surgery 
with CPB.
The secondary objectives are to de-
termine the effects, if any, of LME and 
leucocyte filtration on cerebral and 
renal injury as measured by biochem-
ical and immunological markers, and 
pulmonary function as measured by 
calculation of the respiratory index 
and ITU ventilator settings. Using ITU 
stay, blood product and fluid usage, 
the cost implications for this new 
treatment will be evaluated and com-
pared to the control group; our cur-
rent standard care.
Outcome Measures and Endpoints
The primary outcome measures are 
quantifying LME removal and acti-
vated leucocyte filtration. Lipid mi-
croemboli will be counted and sized 
using light microscopy as previously 
described (Kaza, Cope et al. 2003) 
and activated leucocytes will be an-
alysed with Fluorescence-Activated 
Cell Sorting (FACS) of the leucocyte 
activation maker CD11b during the 
immediate surgical procedure and for 
24 hours following surgery, with ref-
erence values taken pre-surgery, in a 
certified laboratory.
The secondary outcome measures, 
markers of cerebral and renal injury 
(including Neurone-Specific Enolase 
(NSE), and Cystatin C) will be deter-
mined by biochemical/haematolog-
ical analysis. Markers of injury will 
be measured before during and for 
3 days following surgery. Determina-
tion of pulmonary dysfunction will 
be calculated from ITU observation 
charts and calculation of the respira-
tory index.
Due to the variability of patients, 
in terms of biochemical marker val-
ues, subtraction analysis shall be 
employed on all data collected (i.e. 
all values subtracted from baseline 
measurements). 
The study will end once 50 patients 
have completed the study assess-
ments and the data has been ana-
lysed.
Sample Size
In vitro studies have shown that the 
RemoweLL oxygenator removes 40–
50% of leucocytes and 55–70% of li-
pid microparticles. Recent in vivo data 
(unpublished) show that the num-
bers of LME in the RemoweLL sys-
tem compared to a standard circuit is 
1095±579 vs. 2970±1405.29 particles 
/mL giving an average percentage 
removal of 63±8.4%. The number of 
patients in each study group (25) was 
determined by an a priori power cal-
culation using G*Power Version 3.1.0 
(Universität Kiel, Germany) to achieve 
a power (1-β) of 0.95 with α=0.001 
for an effect size index of 1.745 that 
may be expected in clinical practice 
based on the in vivo data. These pow-
er calculations allow for a 15% drop 
out rate or loss to follow up. No data 
is available to indicate the direct re-
lationship that LME and leucocyte 
filtration will have on biochemical 
markers of organ injury; for this rea-
son a post hoc power analysis will be 
undertaken to determine the actual 
achieved power of this study. Previ-
ous studies have shown that the low-
er the serum concentrations of NSE, 
the better the outcome of patients af-
ter CPB (Ali, Harmer et al. 2000). For 
this reason a tentative a priori pow-
er calculation has been undertaken 
based on Bonacchi’s work (Bonacchi, 
Prifti et al. 2006) where the average 
postoperative peak serum NSE con-
centration was 17.7±6.5µg/L. An as-
sumption was made that for a signif-
icant, clinically relevant, difference 
in peak circulating NSE, a minimum 
reduction of 33% (i.e. a one-third re-
duction) should be seen in the study 
group compared to control group as-
suming equal standard deviations in 
Table 1. Inclusion and Exclusion criteria
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both groups. Based upon these as-
sumptions an effect size of 0.923 can 
be calculated. Therefore, a sample 
size of 50 (twenty-five subjects per 
group) is sufficient, with power (1-β) 
of 80% and α=0.05, to show a 33% 
reduction in NSE allowing for a drop 
out or loss to follow up rate of 15%.
Feasibility
At  the study site, approximate-
ly 1800 cardiothoracic procedures 
are undertaken every year, of which 
at least 500 are routine CABGs. 
Based upon data from previous 
years of patients with similar eligi-
bility criteria, it is confirmed that 
10 patients could be enrolled every 
month. Therefore the target sam-
ple size is achievable and, assum-
ing a slow starting period, recruit-
ment should take about 6-8 months.
Sampling Method
All blood samples will be collected 
from the central venous catheter 
and placed into EDTA, lithium hepa-
rin, serum and full blood count tubes 
(depending upon the tests required) 
and processed as soon as possible 
following the end of bypass, or upon 
collection. Samples for CD11b analy-
sis will be kept in ice until processed. 
Measurement Process
All patients will be screened for eli-
gibility and, if appropriate enrolled 
into the study which will have a 
measurement of 4 days. During 
this period blood and urine sam-
ples will be taken at 11 time points.
Screening
When attending the preoperative 
surgical assessment, a patient meet-
ing the inclusion criteria will be ver-
bally informed of the research and 
given a written Patient Information 
Sheet (PIS) in the presence of the 
Consultant Surgeon. Verbal confirma-
tion that the patient has read the PIS 
will be gained, and informed consent 
taken in the presence of an investi-
gator or Consultant Surgeon on the 
evening before surgery. If the patient 
gives written informed consent then 
the patient’s GP will be informed of 
their participation in the trial and 
sent a copy of the PIS. The patient 
may withdraw their consent at any 
time during the study. Once the pa-
tient is consented they are given a 
Study-Specific Identifier (SSI) which 
is used for data analysis throughout 
the study. Patient identifiers are re-
moved from any study data and de-
tails linking patient number and SSI 
will be kept separately to study data 
in a locked filling cabinet in the office 
of SS. If a patient withdraws consent 
during the study, their data will be 
removed from the study analysis. 
Where English is not the patient’s 
first language an interpreter will be 
sought. The Patients will not under-
go any screening process outside of 
the normal remit for CABG surgery. 
Study Period
All subjects will be treated accord-
ing to the local standards at South-
ampton General Hospital. Following 
induction of anaesthesia and place-
ment of central venous and urinary 
catheters, blood and urine samples 
shall be collected for the pre-op-
erative, baseline characteristics. 
The subjects will then undergo routine 
CABG surgery using CPB. During this 
period blood samples will be collect-
ed from the CPB circuit as described in 
Table 2. For the following 3 postoper-
ative mornings, blood and urine sam-
ples will be collected from the subject 
by nursing staff and sent for analysis.
Statistical Methods
The patients will be randomised to ei-
ther the control or study group on the 
morning of surgery using a previously 
compiled randomisation table system 
(QuickCalcs Randomise1, GraphPad 
Software Inc, USA), which will be held 
in the locked office at Southampton 
General Hospital. On the morning of 
surgery the investigating Perfusion-
ist will telephone the office and be 
given the study specific number and 
be told whether the patient is to be 
put into group A or B; with only the 
investigating Perfusionist knowing 
what groups A and B relate to (i.e. 
study or control). Fifty (50) patients 
given a unique study code will be ran-
domised into the study group, (Re-
moweLL, twenty-five patients (25)) or 
control group (Admiral, twenty-five 
patients (25)). Primary and secondary 
endpoints will be analysed using the 
SPSS statistical package by the Prin-
ciple Investigator and independently 
reviewed by a statistician from the 
University of Southampton. As many 
of the parameters will be measured 
at various time points, e.g. C – Re-
active Protein, Repeated Measures 
ANOVA will be undertaken to explore 
differences between groups. Param-
eters will also undergo Analysis of 
Covariance to examine possible cor-
relation. Any parameters showing 
skewed as opposed to normal dis-
tribution shall be log transformed if 
possible. If log transformation is not 
appropriate for the skewed param-
eters then the equivalent non-par-
ametric test shall be performed.
DISCUSSION
Evidence suggests that lipid micro-
emboli are a major cause of mul-
ti-organ dysfunction although the 
area requires further investigation. 
Current strategies for the removal of 
lipid microemboli lack efficacy and 
in some situations are associated 
with increased loss of haemostatic 
integrity (Issitt and Sheppard 2011). 
This study will examine the effica-
cy of lipid and leucocyte filtration in 
patients requiring cardiopulmonary 
bypass for cardiothoracic surgery. 
It is hoped that the results gener-
ated by this study will advance car-
diopulmonary bypass practice and 
provide further areas for research.
Study Status
This trial is funded by Eurosets Med-
ical Devices, Italy, and approval was 
provided from the Oxford Research 
Committee C, Ethics Ref: 10/H0606/30 
on the 24th June 2009 and registered 
on EudraCT, Number: 2009-011503-
23 on the 9th March 2009 and on the 
International Standard Randomised 
Controlled Trial Number Register: IS-
RCTN56462370 on the 20th Septem-
ber 2010. The study formally began 
on the 26th March 2013 and is intend-
ed to be open for about 10 months.
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Table 2. Study Assessment Overview.
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